US 12,153,288 B2
Contact lens
Erwin Si, Alameda, CA (US); Nancy Keir, Pleasanton, CA (US); Yuwen Liu, Dublin, CA (US); and Inna Maltseva, San Francisco, CA (US)
Assigned to COOPERVISION INTERNATIONAL LIMITED, Fareham (GB)
Appl. No. 18/690,276
Filed by CooperVision International Limited, Fareham (GB)
PCT Filed Apr. 5, 2023, PCT No. PCT/GB2023/050907
§ 371(c)(1), (2) Date Mar. 8, 2024,
PCT Pub. No. WO2023/209329, PCT Pub. Date Nov. 2, 2023.
Claims priority of provisional application 63/335,787, filed on Apr. 28, 2022.
Prior Publication US 2024/0264469 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G02C 7/04 (2006.01); B29D 11/00 (2006.01); G02B 1/04 (2006.01)
CPC G02C 7/04 (2013.01) [B29D 11/00076 (2013.01); B29D 11/00096 (2013.01); B29D 11/00192 (2013.01); G02B 1/043 (2013.01); G02C 7/049 (2013.01)] 30 Claims
OG exemplary drawing
 
1. An unworn sterile hydrogel contact lens immersed in a packaging solution and sealed in a package, said contact lens comprising:
a) a polymeric lens body;
b) about 0.25 μg to 10.0 μg of a cooling agent releasably adhered to the polymeric lens body; and
c) an amount of a TRPV1 inhibitor either releasably adhered to the polymeric lens body or present in the packaging solution or both, and
wherein the TRPV1 inhibitor has a first in vitro release profile and the cooling agent has a second in vitro release profile, and the first release profile is faster than the second release profile, based on percent of total loaded amount of the TRPV1 inhibitor and the cooling agent released in an initial 1 to 3 hours of release.